BCG vaccine

(redirected from Calmette-Guerin vaccine)
Also found in: Dictionary, Encyclopedia.
Related to Calmette-Guerin vaccine: bacillus Calmette-Guerin, bacille Calmette-Guérin vaccine

BCG vaccine

 
bacille calmette-guérin vaccine, a tuberculosis vaccine containing living, avirulent, bovine-strain tubercle bacilli (Mycobacterium bovis). It may be administered percutaneously by a special technique using a multiple-puncture disk, intracutaneously, or intradermally, and it cannot be given when the patient is reactive to tuberculin, when acute infectious disease is present, or when there is extensive skin disorder. It offers some protection against tuberculosis but cannot be relied on for total control of the disease. In a high percentage of cases the vaccine causes local ulcers at the site of administration. Public health officials in the United States recommend the use of BCG vaccine only for those persons living in communities having a high rate of tuberculosis cases. After vaccination with BCG, the patient will have a positive response to tuberculin tests. See also BCG solution.

BCG vac·cine

a suspension of an attenuated strain (bacillus Calmette-Guérin) of Mycobacterium tuberculosis, bovine type, which is inoculated into the skin for tuberculosis prophylaxis.

BCG vaccine

(bē′sē-jē′)
n.
A preparation consisting of attenuated human tubercle bacilli that is used for immunization against tuberculosis.

BCG vaccine

A vaccine containing Bacille Calmette-Guérin, an attenuated strain of the bovine tubercle bacillus. The vaccine is used to confer a measure of immunity on people who, on Mantoux or Heaf testing are shown not to have had a primary infection with tuberculosis. It is equally effective in giving protection against leprosy. BCG vaccine is available in a freeze-dried form. The drug is on the WHO official list. (Leon Charles Albert Calmette, 1863–1933, French surgeon, and Camille Guerin, 1872–1961, French veterinary surgeon).

Calmette,

Leon Charles Albert, French bacteriologist, 1863-1933.
Bacille bilié de Calmette-Guérin - an attenuated strain of Mycobacterium bovis used for immunization against tuberculosis and in cancer chemotherapy. Synonym(s): Bacille Calmette-Guérin; Calmette-Guérin bacillus
Bacille Calmette-Guérin - Synonym(s): Bacille bilié de Calmette-Guérin
bacillus Calmette-Guérin vaccine - a vaccine for tuberculosis prophylaxis. Synonym(s): BCG vaccine
Calmette test - conjunctival reaction to tuberculin.
Calmette-Guérin bacillus - Synonym(s): Bacille bilié de Calmette-Guérin
Calmette-Guérin vaccine - Synonym(s): bacillus Calmette-Guérin vaccine
References in periodicals archive ?
Saving lives by training innate immunity with bacilli Calmette-Guerin vaccine. PNAS.
* The original EPI vaccines were Bacille Calmette-Guerin vaccine (BCG) (to protect against tuberculosis), polio vaccine (Pol), measles-containing vaccine (MCV), and diphtheria-tetanus-pertussis vaccine (DTP).
Since 1974, global coverage with the four core vaccines (Bacille Calmette-Guerin vaccine [BCG; for protection against tuberculosis], diphtheria-tetanus-pertussis [DTP] vaccine, poliovirus vaccine, and measles vaccine) has increased from <5% to [greater than or equal to]85%, and additional vaccines have been added to the recommended schedule.
Since then, global coverage with the four core vaccines (Bacille Calmette-Guerin vaccine [for protection against tuberculosis], diphtheria-tetanus-pertussis vaccine [DTP], polio vaccine, and measles vaccine) has increased from <5% to [greater than or equal to]84%, and additional vaccines have been added to the recommended schedule.
We were a bit disappointed that Bacille Calmette-Guerin vaccine was covered in only seven lines, that bed nets were not mentioned for malaria control, that typhoid was not included in the differential diagnosis of lymphocytosis or prolonged fever, that short-course therapy was not recommended for typhoid fever, and that tinidazole or single-dose metronidazole were not suggested for invasive amebiasis.
Worldwide coverage with other recommended vaccines was 89% for bacille Calmette-Guerin vaccine, 84% for the third dose of poliovirus vaccine, 84% for the first dose of measles-containing vaccine, 79% for the third dose of hepatitis B vaccine, and 45% for the third dose of Haemophilus influenzae type b vaccine.
Initially, those vaccines were limited to bacille Calmette-Guerin vaccine (BCG), diphtheria-tetanus-pertussis vaccine (DTP), oral poliovirus vaccine, and measles-containing vaccine (MCV).
Coverage with the other routinely recommended childhood vaccines was 90% for Bacille Calmette-Guerin vaccine, 86% for the third dose of poliovirus vaccine, 85% for measles-containing vaccine, 75% for the third dose of hepatitis B vaccine, and 42% for the third dose of Haemophilus influenzae type b vaccine.
This lack of understanding as to what constitutes an appropriate birth dose of HepB vaccine might reflect the fact that the term "birth dose" also is used widely for bacille Calmette-Guerin vaccine administration a few weeks after birth, and for oral poliovirus vaccine administration several days after birth.
Countries should validate coverage regularly through house-to-house monitoring and/or comparing the number of measles vaccine doses administered to the number of first doses of DTP or the number of doses of Bacille Calmette-Guerin vaccine; 2) Performing follow-up campaigns at least every 4 years and achieving [greater than or equal to]95% vaccination coverage in all municipalities.
Children aged 0-2 months received Bacillus Calmette-Guerin vaccine, those aged 2-9 months received oral poliovirus vaccine (OPV) and diphtheria and tetanus toxoids and pertussis vaccine (DTP), and children aged 9-48 months received OPV and measles vaccine.
In addition, approximately one third of vaccination posts administered additional vaccines recommended by WHO's Expanded Program on Immunization (EPI) to eligible persons based on review of their vaccination records; these vaccines included measles vaccine, bacilie Calmette-Guerin vaccine, and diphtheria and tetanus toxoids and pertussis vaccine for young children and tetanus toxoid for women aged 15-44 years.